Amylyx Pharmaceuticals (NASDAQ:AMLX) Issues Quarterly Earnings Results, Misses Estimates By $0.06 EPS

Amylyx Pharmaceuticals (NASDAQ:AMLX) posted its quarterly earnings data on Tuesday. The company reported ($0.55) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.49) by ($0.06), Zacks reports. The company had revenue of ($0.67) million for the quarter.

Amylyx Pharmaceuticals Trading Up 11.6 %

AMLX opened at $3.36 on Thursday. The company has a market capitalization of $230.32 million, a price-to-earnings ratio of -0.88 and a beta of -0.54. Amylyx Pharmaceuticals has a 12-month low of $1.58 and a 12-month high of $19.32. The business’s fifty day simple moving average is $3.54 and its 200-day simple moving average is $3.86.

Insider Activity at Amylyx Pharmaceuticals

In related news, CEO Justin B. Klee sold 7,471 shares of Amylyx Pharmaceuticals stock in a transaction that occurred on Monday, January 6th. The shares were sold at an average price of $4.04, for a total transaction of $30,182.84. Following the transaction, the chief executive officer now directly owns 3,176,788 shares of the company’s stock, valued at $12,834,223.52. This trade represents a 0.23 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. Also, CEO Joshua B. Cohen sold 11,851 shares of the company’s stock in a transaction on Monday, February 3rd. The stock was sold at an average price of $3.47, for a total value of $41,122.97. Following the sale, the chief executive officer now owns 3,201,247 shares of the company’s stock, valued at approximately $11,108,327.09. This represents a 0.37 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 27,169 shares of company stock worth $97,274 over the last three months. 11.70% of the stock is owned by corporate insiders.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently weighed in on AMLX shares. Baird R W upgraded Amylyx Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a report on Monday, November 18th. Robert W. Baird upgraded Amylyx Pharmaceuticals from a “neutral” rating to an “outperform” rating and increased their target price for the stock from $3.00 to $11.00 in a research note on Monday, November 18th. Finally, HC Wainwright reiterated a “buy” rating and set a $12.00 target price on shares of Amylyx Pharmaceuticals in a research report on Wednesday. Five analysts have rated the stock with a hold rating, three have assigned a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, Amylyx Pharmaceuticals currently has a consensus rating of “Moderate Buy” and a consensus price target of $7.33.

Amylyx Pharmaceuticals Company Profile

Amylyx Pharmaceuticals, Inc, a commercial-stage biotechnology company, engages in the discovery and development of treatment for amyotrophic lateral sclerosis (ALS) and neurodegenerative diseases. The company's products include RELYVRIO, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment of ALS in adults in the United States and marketed as ALBRIOZA for the treatment of ALS in Canada.